Ratings Safe Fertility Group

Equities

End-of-day quote Thailand S.E. Other stock markets 03:30:00 24/05/2024 am IST			5-day change	1st Jan Change
22.1 ^THB	+1.38%		-1.34%	+20.77%

02/05	41,792,822 Ordinary Shares of Safe Fertility Group Public Company Limited are subject to a Lock-Up Agreement Ending on 2-MAY-2024.	CI
26/04	Safe Fertility Group Public Company Limited Approves Dividend, Payable on May 24, 2024	CI

The prospective high growth for the next fiscal years is among the main assets of the company
The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
There is high visibility into the group's activities for the coming years. Outlooks on future revenues from analysts covering the equity remain similar. Such hardly dispersed estimates support highly predictable sales for the current and upcoming fiscal years.
Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.

The company benefits from high valuations in earnings multiples.
The company appears highly valued given the size of its balance sheet.
The company is highly valued given the cash flows generated by its activity.
For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.

	1st Jan change	Capi.	ESG Refinitiv
SAFE FERTILITY GROUP	+20.77%	181M	-
HCA HEALTHCARE, INC.	+17.79%	82.59B	C+
CVS HEALTH CORPORATION	-29.03%	69.86B	B-
DR. SULAIMAN AL HABIB MEDICAL SERVICES GROUP COMPANY	0.00%	26.5B	C+
FRESENIUS SE & CO. KGAA	+3.06%	17.29B	A-
LABCORP HOLDINGS INC.	-12.54%	16.61B	B
QUEST DIAGNOSTICS INCORPORATED	+2.31%	15.56B	A-
NATERA, INC.	+74.08%	13.2B	C-
REDE D'OR SÃO LUIZ S.A.	+0.73%	12.75B	B-
TENET HEALTHCARE CORPORATION	+73.30%	12.6B	C+

Investor Rating

Trading Rating

ESG Refinitiv

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality